Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas.

The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsvćrd, Denmark.

Number of employees : 41 971 persons.
Sales per Businesses
20152016Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care85,59079.3%88,94979.6% +3.92%
Biopharmaceuticals22,33720.7%22,83120.4% +2.21%
Sales per Regions
20152016Delta
DKK (in Million)%DKK (in Million)%
North America56,85752.7%---
Europe20,79819.3%20,68218.5% -0.56%
International14,96613.9%14,05012.6% -6.12%
Region China9,8719.1%10,4589.4% +5.95%
Japan & Korea5,4355%---
United States--57,19451.2%-
Pacific--9,3968.4%-
Managers
NameAgeSinceTitle
Lars Fruergaard Jřrgensen, MBA511991President & Chief Executive Officer
Göran Ando682005Chairman
Jesper Brandgaard, MBA541999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD571991Chief Science Officer & Executive Vice President
Mads Krogsgaard--Chief Science Officer
Anne Marie Handrup Kverneland611981Director
Stig Strřbćk531992Director
Elizabeth Anne Hewitt612012Independent Director
Sřren Thuesen Pedersen, MBA531994Director
Jeppe Fonager Christiansen582013Vice Chairman
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 1,962,564,000 1,753,082,748 89.3% 45,667,252 2.3% 70.1%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.35%
Norges Bank Investment Management 42,958,316 2.19%
The Vanguard Group, Inc. 41,407,145 2.11%
Capital Research & Management Co. (World Investors) 35,054,673 1.79%
Alecta Pension Insurance Mutual 28,698,000 1.46%
Novo Nordisk A/S 21,088,569 1.07%
Northern Cross LLC 20,263,955 1.03%
BlackRock Fund Advisors 17,365,731 0.88%
Jupiter Asset Management Ltd. 15,148,501 0.77%
Swedbank Robur Fonder AB 14,683,423 0.75%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 21,088,5691.07%820,409,443 USD
Nnit A/S (NNIT) 6,375,00025.5%179,681,351 USD
Innate Pharma (IPH) 5,564,70810.3%68,716,854 USD
Pieris Pharmaceuticals Inc (PIRS) 0
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S8.76%81 193
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%235 172
NOVARTIS AG6.07%210 841
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
SANOFI13.94%122 703
BAYER AG17.72%107 272
GLAXOSMITHKLINE PLC5.22%103 536
BRISTOL-MYERS SQUIBB C..-7.65%88 912
ELI LILLY AND CO6.12%86 117
ASTRAZENECA PLC17.79%84 691
ABBOTT LABORATORIES16.40%77 584
ALLERGAN PLC6.24%74 939
SHIRE PLC-0.69%54 018
TAKEDA PHARMACEUTICAL ..19.77%41 272
TEVA PHARMACEUTICAL IN..-26.75%28 799
ASTELLAS PHARMA INC-13.68%27 251
MYLAN NV4.12%21 289
CHUGAI PHARMACEUTICAL ..25.34%21 217
JIANGSU HENGRUI MEDICI..29.43%20 172
Sector Pharmaceuticals - NEC
Novo Nordisk A/S : Connections
Archimedes Pharma UK Ltd.
Hofor Forsyning A/S
Bio*One Capital Pte Ltd.
Maj Invest Holding A/S
EUSA Pharma (Europe) Ltd.
Novo Nordisk Holding Ltd.
RAND Health
Essex Bidco Ltd.
The International Centre for Missing & Exploited Children
Fondsmćglerselskabet Maj Invest A/S (Broker)
Essex Woodlands Health Ventures UK Ltd.
Steno Diabetes Center A/S
Harno Invest A/S
Novo Nordisk Fonden
Novo Nordisk China Pharmaceuticals Co. Ltd.
NNE Pharmaplan A/S
University of Copenhagen
HOFOR Forsyning Holding A/S
SWMF Life Science Venture Fund LP
Silverwood Property Ltd.
Novo Nordisk Region Japan & Korea A/S
Novo Nordisk Region Europe A/S
Novo Nordisk Region International Operations A/S
Hofor Forsyning Komplementar A/S
Novo Nordisk Gsc Holding A/S
Novo Nordisk Pharmaceuticals A/S
Fondsmćglerselskabet Maj Invest A/S
Novo Nordisk Invest 2 A/S
Haldor Topsoe A/S
Novo Nordisk Region China A/S
Novo Nordisk Region North America Ii A/S
SC Triton Industry SRL
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsvćrd, Capital Region 2880

Phone : +45.44.44.88.88
Web : www.novonordisk.com
© 2017 People , Fundamentals and Ownership